Grifols, S.A. (GRFS)

The company now

Grifols reported third-quarter 2026 revenue of EUR 2,040 million on 2 November, up 8.4 percent at constant currency, and net profit of EUR 162 million 1.

Adjusted EBITDA, the company's own measure of operating profit, was EUR 538 million in the quarter, a margin of 26.4 percent 1.

Biopharma, the plasma medicines business, grew 10.3 percent at constant currency in the quarter, led by immunoglobulins at 11.3 percent 1. Albumin fell 13.2 percent, which the company ties to regulation and high inventory in China 1.

Net leverage, debt measured against earnings, fell to 3.98x from 4.2x a year earlier, and liquidity rose to EUR 2,140 million 1. The company said it remains on track to meet its 2026 guidance 1.

The board approved on 30 October an interim dividend of euro 0.15 per share, payable on 4 December 2026 2.

The open question is the Phase 3 SPARTA study of alpha-1 antitrypsin in emphysema, with topline results expected by the end of the fourth quarter of 2026, the company said 1.

As of Nov 4, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.